Brazil has the third-largest outbreak of COVID-19 with 8 million cases and a record 200,000 deaths. After much criticism, the country has now taken a strong interest in the purchase, development, and improvement of tests and vaccines.
Fractioning doses of yellow fever vaccine can help save more lives
Format
An MSF/Epicentre study has found giving one-fifth of a normal dose of yellow fever vaccine provides protection.
The disease can be deadly and is incurable, claiming 300,000 lives each year; outbreaks in Africa are common.
The study findings will allow for more people to be vaccinated – and lives saved – during sudden outbreaks of the disease.
NEW YORK/PARIS - Giving people a fraction of a yellow fever vaccine is effective and could help vaccinate millions more people during emergencies, according to results of a recent study led by Médecins Sans Frontiéres’ (MSF) research arm Epicentre, published in The Lancet. These clinical trial results, which found that giving a person one-fifth of the standard yellow fever vaccine dose is effective and safe, will make it easier for governments and international organisations to prevent people from getting sick from yellow fever during outbreaks in times of vac
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine usi
News Category Global Banking & Finance Reviews
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration an